S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
Top-Rated StocksTop-RatedMost-Upgraded StocksMost-Upgraded

Immunovant (IMVT) Earnings Date, Estimates & Call Transcripts

$39.19
-1.08 (-2.68%)
(As of 12/8/2023 ET)
Compare
Today's Range
$38.57
▼
$40.26
50-Day Range
$31.31
▼
$40.81
52-Week Range
$14.05
▼
$44.19
Volume
972,778 shs
Average Volume
1.33 million shs
Market Capitalization
$5.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.62
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Feb. 2Estimated
Actual EPS
(Nov. 9)
-$0.45
Consensus EPS
(Nov. 9)
-$0.45
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

IMVT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

IMVT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Immunovant Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20231($0.42)($0.42)($0.42)
Q2 20231($0.47)($0.47)($0.47)
Q3 20232($0.52)($0.43)($0.48)
Q4 20234($0.47)($0.36)($0.42)
FY 20238($1.88)($1.68)($1.78)
Q1 20243($0.48)($0.42)($0.45)
Q2 20245($0.49)($0.41)($0.45)
Q3 20244($0.55)($0.45)($0.49)
Q4 20244($0.55)($0.42)($0.48)
FY 202416($2.07)($1.70)($1.87)
Q1 20252($0.63)($0.55)($0.59)
Q2 20252($0.60)($0.51)($0.56)
Q3 20252($0.63)($0.49)($0.56)
Q4 20252($0.63)($0.46)($0.55)
FY 20258($2.49)($2.01)($2.25)
Q1 20261($0.44)($0.44)($0.44)

IMVT Earnings Date and Information

Immunovant last announced its earnings results on November 9th, 2023. The reported ($0.45) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.45). Immunovant has generated ($1.97) earnings per share over the last year (($1.97) diluted earnings per share). Earnings for Immunovant are expected to decrease in the coming year, from ($1.82) to ($1.88) per share. Immunovant has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, February 2nd, 2024 based off prior year's report dates.

Immunovant Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/2/2024
Estimated)		------- 
11/9/2023Q2 2024($0.45)($0.45)-($0.45)--
8/10/2023Q1 2024($0.44)($0.47)($0.03)($0.37)--
5/22/2023Q1 2023($0.41)($0.46)($0.05)($0.46)--
2/3/2023Q3 2023($0.41)($0.49)($0.08)($0.49)--
11/4/2022Q2 2023($0.41)($0.41)-($0.41)--
8/5/2022Q1 2023($0.40)($0.35)+$0.05($0.35)--
6/8/2022Q4 2022($0.38)($0.41)($0.03)($0.41)--
2/4/2022Q3 2022($0.34)($0.36)($0.02)($0.36)--
11/5/2021Q3 2021($0.26)($0.35)($0.09)($0.35)--
8/9/2021Q2 2021($0.31)($0.31)-($0.31)--    
5/31/2021Q1 2021($0.33)($0.29)+$0.04($0.29)--
2/16/2021Q4 2020($0.25)($0.32)($0.07)($0.32)--












Immunovant Earnings - Frequently Asked Questions

When is Immunovant's earnings date?

Immunovant has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, February 2nd, 2024 based off last year's report dates. Learn more on IMVT's earnings history.

Did Immunovant beat their earnings estimates last quarter?

In the previous quarter, Immunovant (NASDAQ:IMVT) reported ($0.45) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.45). Learn more on analysts' earnings estimate vs. IMVT's actual earnings.

How much profit does Immunovant generate each year?

Immunovant (NASDAQ:IMVT) has a recorded net income of -$210.96 million. IMVT has generated -$1.97 earnings per share over the last four quarters.

What is Immunovant's EPS forecast for next year?

Immunovant's earnings are expected to decrease from ($1.82) per share to ($1.88) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:IMVT) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -